drugset
drugset / Trial / NCT01651234

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers

NCT01651234 ↗

Phase 1 Completed 48 enrolled Green Cross Corporation Quintiles, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and characterize the PK, PD f\\profile.

Timeline

Start
2012-03
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject GCC-4401 Unknown 2.5 mg Oral
Subject GCC-4401 Unknown 5 mg Oral
Subject GCC-4401 Unknown 10 mg Oral
Subject GCC-4401 Unknown 20 mg Oral
Subject GCC-4401 Unknown 40 mg Oral
Subject GCC-4401 Unknown 80 mg Oral

Indications

No indication recorded.